These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 37459349)
1. Optimizing antiretroviral therapy for children living with HIV: Experience from an observational cohort in Lesotho. Tukei VJ; Herrera N; Masitha M; Masenyetse L; Mokone M; Mokone M; Maile L; Gill MM PLoS One; 2023; 18(7):e0288619. PubMed ID: 37459349 [TBL] [Abstract][Full Text] [Related]
2. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492 [TBL] [Abstract][Full Text] [Related]
4. Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe. Pasipanodya B; Kuwengwa R; Prust ML; Stewart B; Chakanyuka C; Murimwa T; Brophy J; Salami O; Mushavi A; Apollo T J Int AIDS Soc; 2018 Dec; 21(12):e25214. PubMed ID: 30549217 [TBL] [Abstract][Full Text] [Related]
5. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. Barlow-Mosha L; Angelidou K; Lindsey J; Archary M; Cotton M; Dittmer S; Fairlie L; Kabugho E; Kamthunzi P; Kinikar A; Mbengeranwa T; Msuya L; Sambo P; Patel K; Barr E; Jean-Phillipe P; Violari A; Mofenson L; Palumbo P; Chi BH Clin Infect Dis; 2016 Oct; 63(8):1113-1121. PubMed ID: 27439527 [TBL] [Abstract][Full Text] [Related]
6. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial. Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V; BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406 [TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa. Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231 [TBL] [Abstract][Full Text] [Related]
8. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study). Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Urda L; Amstutz A; Tschumi N; Klimkait T; Labhardt ND HIV Med; 2022 Mar; 23(3):287-293. PubMed ID: 34632682 [TBL] [Abstract][Full Text] [Related]
9. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial. Murnane PM; Strehlau R; Shiau S; Patel F; Mbete N; Hunt G; Abrams EJ; Coovadia A; Kuhn L Clin Infect Dis; 2017 Aug; 65(3):477-485. PubMed ID: 28419200 [TBL] [Abstract][Full Text] [Related]
10. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Lindsey JC; Hughes MD; Violari A; Eshleman SH; Abrams EJ; Bwakura-Dangarembizi M; Barlow-Mosha L; Kamthunzi P; Sambo PM; Cotton MF; Moultrie H; Khadse S; Schimana W; Bobat R; Zimmer B; Petzold E; Mofenson LM; Jean-Philippe P; Palumbo P; Pediatr Infect Dis J; 2014 Aug; 33(8):846-54. PubMed ID: 25222305 [TBL] [Abstract][Full Text] [Related]
11. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Kuhn L; Coovadia A; Strehlau R; Martens L; Hu CC; Meyers T; Sherman G; Hunt G; Persaud D; Morris L; Tsai WY; Abrams EJ Lancet Infect Dis; 2012 Jul; 12(7):521-30. PubMed ID: 22424722 [TBL] [Abstract][Full Text] [Related]
12. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. Ruel TD; Kakuru A; Ikilezi G; Mwangwa F; Dorsey G; Rosenthal PJ; Charlebois E; Havlir D; Kamya M; Achan J J Acquir Immune Defic Syndr; 2014 Apr; 65(5):535-41. PubMed ID: 24326597 [TBL] [Abstract][Full Text] [Related]
13. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. Lockman S; Hughes M; Sawe F; Zheng Y; McIntyre J; Chipato T; Asmelash A; Rassool M; Kimaiyo S; Shaffer D; Hosseinipour M; Mohapi L; Ssali F; Chibowa M; Amod F; Halvas E; Hogg E; Alston-Smith B; Smith L; Schooley R; Mellors J; Currier J; PLoS Med; 2012; 9(6):e1001236. PubMed ID: 22719231 [TBL] [Abstract][Full Text] [Related]
14. Growth Recovery Among HIV-infected Children Randomized to Lopinavir/Ritonavir or NNRTI-based Antiretroviral Therapy. Achan J; Kakuru A; Ikilezi G; Mwangwa F; Plenty A; Charlebois E; Young S; Havlir D; Kamya M; Ruel T Pediatr Infect Dis J; 2016 Dec; 35(12):1329-1332. PubMed ID: 27580060 [TBL] [Abstract][Full Text] [Related]
15. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir. Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494 [TBL] [Abstract][Full Text] [Related]
16. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study. Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514 [TBL] [Abstract][Full Text] [Related]
17. Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort. Amani-Bosse C; Dahourou DL; Malateste K; Amorissani-Folquet M; Coulibaly M; Dattez S; Emieme A; Barry M; Rouzioux C; N'gbeche S; Yonaba C; Timité-Konan M; Mea V; Ouédraogo S; Blanche S; Meda N; Seguin-Devaux C; Leroy V J Int AIDS Soc; 2017 Apr; 20(1):21362. PubMed ID: 28453240 [TBL] [Abstract][Full Text] [Related]
18. Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older. Alvarez-Uria G; Pakam R; Naik PK; Midde M PLoS One; 2014; 9(9):e108063. PubMed ID: 25232730 [TBL] [Abstract][Full Text] [Related]
19. Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice. Gondrie IPE; Bastiaans DET; Fraaij PLA; Driessen GJA; van der Knaap LC; Visser EG; van Jaarsveld P; de Groot R; Hartwig NG; Burger DM; van Rossum AMC Pediatr Infect Dis J; 2017 Oct; 36(10):976-980. PubMed ID: 28475554 [TBL] [Abstract][Full Text] [Related]
20. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Sturt AS; Dokubo EK; Sint TT Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]